#ASCO22 – Phase II RCT: Ramucirumab and pembrolizumab vs. standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy.

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A – Journal of Clinical Oncology

Commentary: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network

Commentary on Twitter

https://twitter.com/JCO_ASCO/status/1532785457947414531